TrialThe Lancet. Oncology2024

Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study.

Othon Iliopoulos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.